Back to Search Start Over

FRI0248 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY IN PRIMARY SJÖGREN SYNDROME: A MARKER OF EROSIONS ON HIGH RESOLUTION ULTRASOUND OF HANDS AND WRISTS

Authors :
Elaine P. Leon
Karina Bonfiglioli
Margarete Borges Galhardo Vendramini
Lissiane Karine Noronha Guedes
Tamyris Bocate
Sandra Gofinet Pasoto
Eloisa Bonfa
Source :
Poster Presentations.
Publication Year :
2019
Publisher :
BMJ Publishing Group Ltd and European League Against Rheumatism, 2019.

Abstract

Background: Cyclic citrullinated peptides antibodies (anti-CCP) were described in primary Sjogren’s syndrome (pSS). However, its possible associations with joint erosions, synovitis and tenosynovitis on high resolution ultrasonography of hands and wrists (US) in pSS are uncertain. Objectives: To assess in pSS the US findings, and their possible associations with anti-CCP. Methods: We have evaluated 97 consecutive pSS patients (2016 ACR/EULAR Classification Criteria), of both sexes, aged 18-76 years, and without meeting the 1987 ACR classification criteria for rheumatoid arthritis (RA). Twenty RA patients (disease duration Results: Frequency of tenosynovitis on US was higher in the pSS group than in healthy controls (36.1 vs. 3.8%, p Conclusion: US detected higher frequencies of tenosynovitis and erosions in pSS patients than in healthy controls, and the numbers of synovitis and tenosynovitis correlated with ESSDAI, suggesting that US is an important tool for the evaluation of these patients. Moreover, grade 2/3 synovitis and moderate/large erosions appear to be relevant for the distinction between pSS and RA. The additional observation that erosions are associated with anti-CCP in pSS seems to characterize a subgroup of patients with a severe underlying mechanism of joint damage. Grant from FAPESP: 2015/03756-4. References: [1] Riente L, Scire CA, Delle Sedie A, et al. Ultrasound imaging for the rheumatologist. XXIII. Sonographic evaluation of hand joint involvement in primary Sjogren’s syndrome. Clin Exp Rheumatol. 2009;27(5):747-50. Disclosure of Interests: Lissiane Guedes: None declared, Elaine Leon: None declared, Margarete Vendramini: None declared, Tamyris Bocate: None declared, Karina Bonfiglioli Speakers bureau: Has received speaking fees from Roche, Pfizer, Bristol-Myers Squibb, Abbvie and Janssen., Eloisa Bonfa: None declared, Sandra Pasoto: None declared

Details

Database :
OpenAIRE
Journal :
Poster Presentations
Accession number :
edsair.doi...........f2d65d7af64badc26eee9ffe3ad211f2
Full Text :
https://doi.org/10.1136/annrheumdis-2019-eular.4336